FDA approves Viva CRT-P pacemaker for Heart Failure and AV Block - Medtronic
Medtronic, Inc. has announced the FDA approval of its newest cardiac resynchronization therapy-pacemaker, Viva CRT-P, for indicated patients with Heart Failure or Atrioventricular (AV) Block. The Viva CRT-P includes the Medtronic-exclusive AdaptivCRT algorithm, which preserves normal heart rhythms and automatically adjusts to the patient's needs, creating a customized therapy for each patient. It is the only algorithm demonstrated to improve heart failure patients' response to the therapy and reduce the risk of atrial fibrillation, or AF (as compared to conventional biventricular therapy).
Recent data also show the AdaptivCRT algorithm reduced 30-day hospital readmissions for heart failure by 47 percent and AF-related healthcare utilizations (hospitalizations, emergency department or clinic visits) by 55 percent - important benefits since Heart Failure is a costly problem and represents a leading cause of 30-day hospital readmissions
.Medtronic, Inc. secured CE (Conformit� Europ�enne) Mark receipt in May 2014 and the European launch of Viva CRT-P.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins